Penno M B, August J T, Baylin S B, Mabry M, Linnoila R I, Lee V S, Croteau D, Yang X L, Rosada C
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
Cancer Res. 1994 Mar 1;54(5):1381-7.
CD44 is an integral membrane glycoprotein that functions as a receptor for the extracellular matrix glycan, hyaluronan. Here we report that CD44 is a novel biomarker for non-small cell lung tumors, squamous metaplasia of the lung, and activated type II pneumocytes. We have examined the expression of CD44 in 12 human lung tumor cell lines and 23 fixed, paraffin-embedded lung cancers. CD44 transcription and translation is consistently high among non-small cell tumors (5 of 5 cell lines, 10 of 14 tumors) but rare in small cell tumors (1 of 6 cell lines, 0 of 9 tumors). In normal lung, CD44 was confined to the surface of bronchial basal cells and alveolar macrophages. Squamous metaplasia of the lung showed strong CD44 immunoreactivity. Resting type II pneumocytes were largely CD44 negative but rows of active, surfactant-secreting type II cells had significant amounts of CD44 located on lateral surfaces of adjacent cells. The correlation between CD44 and the non-small cell phenotype was further demonstrated in studies of a cultured small cell lung cancer line induced to exhibit characteristics of a non-small lung cancer by infection with v-Ha-ras. Following ras gen insertion, these cells showed a 40-fold increase in CD44 expression. The CD44 detected in lung cancer cells throughout these studies was predominantly the "standard" rather than the "variant" species. Taken together, these results suggest that CD44 is a protein expressed on non-small cell lung tumors, squamous metaplasia, and activated type II cells. In addition, CD44 in cultured small cell lung cancer cells is transcriptionally activated following differentiation by the ras oncogene. The fact that immunohistochemistry can be used to discriminate among the cell types makes CD44 a valuable new marker for lung neoplasia.
CD44是一种整合膜糖蛋白,作为细胞外基质聚糖透明质酸的受体发挥作用。在此我们报告,CD44是一种用于非小细胞肺癌、肺鳞状化生和活化II型肺细胞的新型生物标志物。我们检测了12个人类肺肿瘤细胞系和23例固定的石蜡包埋肺癌组织中CD44的表达。CD44的转录和翻译在非小细胞肿瘤中始终较高(5个细胞系中的5个,14个肿瘤中的10个),但在小细胞肿瘤中罕见(6个细胞系中的1个,9个肿瘤中的0个)。在正常肺组织中,CD44局限于支气管基底细胞和肺泡巨噬细胞表面。肺鳞状化生显示出强烈的CD44免疫反应性。静止的II型肺细胞大多为CD44阴性,但一排排活跃的、分泌表面活性物质的II型细胞在相邻细胞的侧面有大量CD44。在一项研究中,通过感染v-Ha-ras诱导培养的小细胞肺癌细胞系表现出非小细胞肺癌的特征,进一步证明了CD44与非小细胞表型之间的相关性。在插入ras基因后,这些细胞的CD44表达增加了40倍。在这些研究中,在肺癌细胞中检测到的CD44主要是“标准”型而非“变异”型。综上所述,这些结果表明CD44是一种在非小细胞肺癌、鳞状化生和活化II型细胞上表达的蛋白质。此外,培养的小细胞肺癌细胞中的CD44在被ras癌基因诱导分化后转录激活。免疫组织化学可用于区分细胞类型这一事实使CD44成为一种有价值的新型肺肿瘤标志物。